{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Faad25gooderham-gsF_JqSn","width":444,"version":"1.0","type":"rich","title":"Melinda Knows Best: AAD 2025 Orlando Hands Up with Dr.Melinda Gooderham ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/c5e333d4-1159-478d-8fab-1b8e294b2dfa/newt.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/9800a65e-ac9b-4514-a5f6-a1409278d9d4\" height=\"200\" width=\"100%\" title=\"Melinda Knows Best: AAD 2025 Orlando Hands Up with Dr.Melinda Gooderham \" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"🙌 Hands Down at AAD 2025: Delgocitinib and the “Super-Responder” Story 🌴🎧\n\n🐶✨ Puppies in the hall, Snoop after dark, and a late-breaker that might change how you treat chronic hand eczema on Monday. In this AAD 2025 mini-episode of our “Melinda Knows Best” series, Dr. Melinda Gooderham unpacks a fresh subgroup analysis from the DELTA 1/2/3 program in chronic hand eczema (CHE)—what a “super responder” actually is, how long clearance can last off-therapy, and where a non-steroidal topical like delgocitinib could fit for real patients with real lives (and real world adherence). 🖐️🧴\n\nWhy queue this up? 🔥 Because it’s rare to get practice-ready signals for CHE: about half of patients hit at least one deep patient-reported threshold by Week 16, and—here’s the eye-opener—after stopping therapy at Week 16, ~⅓ were still clear/almost clear at 8 weeks and ~15% at 12 weeks. 📊⏱️\n\n🎯 What you’ll learn:\n\n🧭Define “super responder” in CHE via three lenses:\n📝Read the right scales fast: quick-hit use of HESD, HECSI, and IGA-CHE—and how to translate them into patient-friendly goals.\n⏳Set expectations on durability: what “clear/almost clear” really means (that IGA-CHE bar is high) and how to discuss planned pauses without fueling steroid-withdrawal anxiety.\n🧴Position a topical, non-steroidal JAK inhibitor thoughtfully: where a topical, non-steroidal JAK inhibitor can slot alongside—or instead of—steroids/phototherapy in moderate–severe CHE, especially for adherence-sensitive hands.\n🔁Bridge trials to the clinic rooms: a simple CHE workflow (start → measure → decide → pause → rescue → re-start) anchored to PROs and signs you can track in under 60 seconds.\n\n🔊 Teaser sound bites\n\n“Not all ‘super responders’ are the same—PROs, consistency, and maintenance tell different parts of the story.” 🎯\n“Clear/almost clear on IGA-CHE is a stringent bar—set it, explain it, and celebrate it.” ✅\n\n🎙️ Hit play for late-breaker highlights🌴😅\n\n#AAD2025 #Dermatology #ChronicHandEczema #CHE #Delgocitinib #TopicalJAK #JAKInhibitors #EczemaCare #HECSI #HESD #IGACHE #PROs #LateBreaker #EvidenceBased #HCP #Derms #GPs #SkinAndJointsPodcast #MelindaKnowsBest #Orlando\n\nABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)\n\nToronto, ON\n\nMelinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.\n\nDr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.\n\n📻www.skinandjoints.ca\n\n✉️info@skinandjoints.ca\n\n\n\n"}